# A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

> **NCT05896371** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CHU de Quebec-Universite Laval** · enrollment: 500 (estimated)

## Conditions studied

- Cancer
- Prostate Cancer
- Metastatic Cancer
- Metastatic Prostate Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-I&T - escalating renal absorbed dose
- **DRUG:** 177Lu-PSMA-I&T - recommended phase 2 regime

## Key facts

- **NCT ID:** NCT05896371
- **Lead sponsor:** CHU de Quebec-Universite Laval
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2028-03
- **Primary completion:** 2033-03
- **Final completion:** 2034-03
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896371, "A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05896371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*